These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30273482)

  • 1. Phosphorylation Alters the Residual Structure and Interactions of the Regulatory L1 Linker Connecting NBD1 to the Membrane-Bound Domain in SUR2B.
    Sooklal CR; López-Alonso JP; Papp N; Kanelis V
    Biochemistry; 2018 Nov; 57(44):6278-6292. PubMed ID: 30273482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation-dependent changes in nucleotide binding, conformation, and dynamics of the first nucleotide binding domain (NBD1) of the sulfonylurea receptor 2B (SUR2B).
    de Araujo ED; Alvarez CP; López-Alonso JP; Sooklal CR; Stagljar M; Kanelis V
    J Biol Chem; 2015 Sep; 290(37):22699-714. PubMed ID: 26198630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperinsulinism-Causing Mutations Cause Multiple Molecular Defects in SUR1 NBD1.
    Alvarez CP; Stagljar M; Muhandiram DR; Kanelis V
    Biochemistry; 2017 May; 56(18):2400-2416. PubMed ID: 28346775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful development and use of a thermodynamic stability screen for optimizing the yield of nucleotide binding domains.
    de Araujo ED; Kanelis V
    Protein Expr Purif; 2014 Nov; 103():38-47. PubMed ID: 25153533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) channels.
    Yamada M; Kurachi Y
    J Mol Cell Cardiol; 2005 Jul; 39(1):1-6. PubMed ID: 15978900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR and fluorescence studies of drug binding to the first nucleotide binding domain of SUR2A.
    López-Alonso JP; de Araujo ED; Kanelis V
    Biochemistry; 2012 Nov; 51(45):9211-22. PubMed ID: 23078514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.
    Schwanstecher M; Sieverding C; Dörschner H; Gross I; Aguilar-Bryan L; Schwanstecher C; Bryan J
    EMBO J; 1998 Oct; 17(19):5529-35. PubMed ID: 9755153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of KATP channels to cellular metabolic disorders and the underlying structural basis.
    Li CG; Cui WY; Wang H
    Acta Pharmacol Sin; 2016 Jan; 37(1):134-42. PubMed ID: 26725741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells.
    Yokoshiki H; Sunagawa M; Seki T; Sperelakis N
    Am J Physiol; 1998 Jan; 274(1):C25-37. PubMed ID: 9458709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation in nucleotide-binding domains of sulfonylurea receptor 2 evokes Na-ATP-dependent activation of ATP-sensitive K+ channels: implication for dimerization of nucleotide-binding domains to induce channel opening.
    Yamada M; Ishii M; Hibino H; Kurachi Y
    Mol Pharmacol; 2004 Oct; 66(4):807-16. PubMed ID: 15258252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ZD0947, a novel and potent ATP-sensitive K
    Mori K; Yamashita Y; Teramoto N
    Eur J Pharmacol; 2016 Nov; 791():773-779. PubMed ID: 27693800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
    Cui Y; Tinker A; Clapp LH
    Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.
    Felsch H; Lange U; Hambrock A; Löffler-Walz C; Russ U; Carroll WA; Gopalakrishnan M; Quast U
    Br J Pharmacol; 2004 Apr; 141(7):1098-105. PubMed ID: 15023854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoflurane activates sarcolemmal adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells: a role for protein kinase A.
    Tanaka K; Kawano T; Nakamura A; Nazari H; Kawahito S; Oshita S; Takahashi A; Nakaya Y
    Anesthesiology; 2007 May; 106(5):984-91. PubMed ID: 17457130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.
    Dörschner H; Brekardin E; Uhde I; Schwanstecher C; Schwanstecher M
    Mol Pharmacol; 1999 Jun; 55(6):1060-6. PubMed ID: 10347249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
    Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
    Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proximal C-terminal domain of sulphonylurea receptor 2A interacts with pore-forming Kir6 subunits in KATP channels.
    Rainbow RD; James M; Hudman D; Al Johi M; Singh H; Watson PJ; Ashmole I; Davies NW; Lodwick D; Norman RI
    Biochem J; 2004 Apr; 379(Pt 1):173-81. PubMed ID: 14672537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-terminal transmembrane domain (TMD0) and a cytosolic linker (L0) of sulphonylurea receptor define the unique intrinsic gating of KATP channels.
    Fang K; Csanády L; Chan KW
    J Physiol; 2006 Oct; 576(Pt 2):379-89. PubMed ID: 16887879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain.
    Howell LD; Borchardt R; Kole J; Kaz AM; Randak C; Cohn JA
    Biochem J; 2004 Feb; 378(Pt 1):151-9. PubMed ID: 14602047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A key role for the subunit SUR2B in the preferential activation of vascular KATP channels by isoflurane.
    Fujita H; Ogura T; Tamagawa M; Uemura H; Sato T; Ishida A; Imamaki M; Kimura F; Miyazaki M; Nakaya H
    Br J Pharmacol; 2006 Nov; 149(5):573-80. PubMed ID: 17001304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.